Product Images Atropine Sulfate

This text provides dosing guidelines for the administration of medications in preoperative and emergency scenarios. It includes instructions for initial doses, continued treatment, and maximum total doses for various conditions such as bradycardia, poisoning by organophosphates, carbamates, or muscarinic agents. The document also emphasizes caution when using atropine in certain types of bradyarrhythmias.*

This text provides information on the use of Atropine in various medical scenarios such as preanesthesia, during surgery, and in cases of poisonings. It includes dosages based on age groups and conditions like symptomatic bradycardia. The text also mentions the use of Atropine in emergency situations, excluding routine use in critically ill infants and children during intubation, and its limited effect on bradycardia in patients with transplanted hearts. Atropine is administered through various routes like IV, IM, SC, IO, and ET, with guidelines for repeated doses and maximum total doses.*

This is information about a medication presented in two options: a single vial containing 8 mg per 20 mL or a 10 vial pack each containing 4 mg per mL. The product has a National Drug Code (NDC) of 63323-580-03 for the single vial and 63323-580-20 for the 10 vial pack. The vials are described as multiple-dose vials and come in a 20 mL volume, with each pack containing 10 vials.*

This is information regarding Atropine Sulfate injection solution with a concentration of 0.4 mg per mL and a total volume of 20 mL in a multiple-dose vial. The medication is suitable for intravenous, intramuscular, subcutaneous, intraosseous, or endotracheal administration. It is important to store the product between 20 to 25°C (68 to 77°F) after opening and to discard any remaining solution within 24 hours. The manufacturer is Mir: Fresenius K, and the product is packaged by Henry Schein, Inc. The text also mentions the NDC number, item number, and recommends referring to the manufacturer's insert for complete product and prescribing information.*